Novel Live-Attenuated Rabies Vaccine


The critical feature of this technology is the Evelyn-Rokitnicki-Abelseth (ERA) rabies whole genome DNA sequence. With the availability of the entire rabies genome, a recombinant vaccine can be developed using reverse genetics. Using this technology, CDC researchers have developed a recombinant, live-attenuated vaccine shown to confer protection against lethal doses of live, street-rabies virus in multiple survival studies. This vaccine offers better protection than traditional inactivated vaccinations, as demonstrated in co-infection studies. Further, a single intramuscular vaccination with the CDC's attenuated-virus was sufficient for survival of 100% of hamsters and mice following lethal challenge.

Potential Commercial Applications: Competitive Advantages:
  • Rabies vaccine design and development
  • Immunogenic compositions for both prevention and treatment of rabies virus
  • Rabies virus research
 
  • Live attenuated vaccine shows greater efficacy than older inactivated vaccine
  • 100% animal survival conferred by a single inoculation before lethal challenge


Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Related Invention(s):
E-256-2013-0


Inventors:

Xianfu Wu (CDC)  ➽ more inventions...

Charles Rupprecht (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,863,041 issued 2011-01-04
U.S. Pat: 8,865,461 issued 2014-10-21
US Application No. 12/090,083
US Application No. 12/956,949

Publications:
Wu X, et al. PMID 21514343
Wu X, et al. PMID 17681631
Bankovskiy D, et al. PMID 18634508
Wu X, Rupprecht CE. PMID 17850911
Franka R, et al. PMID 21514343

Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-326-2013-0
Updated: Nov 15, 2013